OBJECTIVE: Obesity in rodents and humans is mostly associated with elevated plasma leptin concentrations, suggesting a new pathological concept of 'leptin resistance'. We have demonstrated that brain-derived neurotrophic factor (BDNF) can improve obesity and diabetes of C57BL/KsJ db/db (db/db) mice. In this study, we investigated whether or not BDNF is effective in two different models of leptin resistance, an acquired model and a genetic model. DESIGN: C57BL/6J mice rendered obese by consumption of a high-fat diet (diet-induced obesity (DIO) mice) were used as an acquired model and lethal yellow agouti mice (KKA y mice) as a genetic model of leptin resistance. Food intake and glucose metabolism were studied after acute or repetitive administration of BDNF. RESULTS: Intraperitoneal administration of BDNF (10 mg/kg, twice/day) significantly reduced cumulative food intake of DIO and KKA y mice, whereas they were unresponsive to leptin administration. Repetitive subcutaneous administration of BDNF (10 mg/kg daily for 6 days) reduced food intake and improved impaired glucose tolerance in DIO mice. Pair feeding of vehicletreated DIO mice with the same amount of chow consumed by the BDNF-treated group did not improve the impaired glucose homeostasis, indicating that the antidiabetic effect is not due to decreased food intake. We also observed that BDNF is effective in improving obesity and diabetes of KKA y mice. CONCLUSION: This study demonstrated antiobesity and antidiabetic effects of BDNF in two different models of leptin resistance, thereby suggesting the therapeutic potential of BDNF in the treatment of leptin-resistant obesity and diabetes.
Introduction
Obesity comprises a heterogeneous group of disorders that arise from complex interactions between genetic predisposition and environmental factors, conferring a higher risk of lifestyle-related cardiovascular and metabolic disorders, such as hypertension, diabetes and hyperlipidemia. 1 Leptin is an adipocyte-derived blood-borne satiety factor that acts directly on the hypothalamus, thereby leading to a significant reduction of body weight by its ability to decrease food intake and to increase energy expenditure. 2 The ob/ob mice, genetically lacking functional leptin, are hyperphagic and obese. Exogenous administration of leptin is highly effective in reversing the obese phenotype in these mice. 3, 4 Furthermore, human subjects with leptin gene mutations are markedly obese 5, 6 and lose weight in response to exogenous administration of leptin. 7 However, human obesity is not usually associated with leptin deficiency, 8 but largely with high circulating levels of leptin (hyperleptinemia), which are in proportion to the degree of adiposity. 9 Endogenous hyperleptinemia may not reduce appetite nor increase energy expenditure in obese rodents and humans, a pathological state termed 'leptin resistance'. Indeed, leptin therapy even at supraphysiological doses is mostly ineffective in reducing body weight of clinically obese subjects. 10, 11 Thus, new therapeutic strategies that can improve or circumvent leptin resistance are an important challenge for obesity research. Brain-derived neurotrophic factor (BDNF) belongs to a family of neurotrophins and plays a crucial role in the survival and differentiation of central and peripheral neurons. 12 We and other groups have reported that peripheral injection of BDNF produces hypophagic and hypoglycemic effects in obese hyperglycemic animals, indicating antiobesity and antidiabetic effects. [13] [14] [15] [16] We have also found that BDNF treatment prevents body temperature reduction during cold exposure or food deprivation, indicating the enhancement of energy expenditure. 17 The above pharmacological effects were reproduced by intracerebroventricular (ICV) injection of very small amounts of BDNF. 16 Since the BDNF receptor, TrkB, is expressed in the hypothalamic nuclei important for body weight regulation, 18 it is likely that antiobesity and antidiabetic effects of BDNF are mediated via a hypothalamic mechanism. Recently, it was reported that heterozygous BDNF +/À mice show hyperphagia and obesity accompanied by hyperinsulinemia, 19, 20 suggesting that BDNF plays a physiological role in the regulation of food intake and glucose homeostasis.
There are a large number of rodent models of obesity, both acquired and genetic. 21, 22 For instance, normal mice fed a high-fat diet (diet-induced obesity (DIO) mice) develop obesity and impaired glucose tolerance. DIO mice show elevated serum leptin concentrations and cannot respond to exogenous administration of leptin. [23] [24] [25] We have also observed that transgenic skinny mice overexpressing leptin 26 develop obesity and impaired glucose tolerance in response to a high-fat diet (Hidaka S et al, unpublished data). In contrast, lethal yellow agouti mice (KKA y mice), a genetically determined rodent model of leptin resistance, develop a late-onset obesity and type II diabetes due to antagonism of the hypothalamic melanocortin system by ectopic expression of the agouti protein. 27 The obese and diabetic phenotypes of KKA y mice are not reversed by transgenic overexpression of leptin. 28 Thus, both DIO and KKA y mice may serve as useful models of leptin-resistant obesity and diabetes. Melanocortin peptides derived from the proopiomelanocortin (POMC) gene, including a-melanocyte stimulating hormone (a-MSH), have been implicated in the regulation of feeding behavior.
1 In order to elucidate whether the BDNF action is involved in the hypothalamic melanocortin system or not, the effect of administration with a potent antagonist of a-MSH, SHU9119, 29 was studied in db/db mice. Given that BDNF is effective in db/db mice lacking the functional leptin receptor, 16 we speculated that BDNF may be capable of circumventing leptin resistance. Thus, the aim of this study was to examine whether or not BDNF is effective in leptin-resistant obesity and diabetes.
Materials and methods

Animals and diet
Male C57BL/6J mice (3 weeks) were purchased from Japan CLEA (Tokyo, Japan). They were given free access to water and either a standard diet (F4031; 15% of calories as fat) or a high-fat diet (F3282; 58% of calories as fat) (Bio-serv, Frenchtown, NJ, USA) for 4 months. Body weights of mice fed either standard or high-fat diets were an average of 28.4 or 45.7 g at 20 weeks of age (n ¼ 24 each). Male KKA y and C57BL/KsJ-db/db mice were obtained from Japan CLEA and used at 11-12 weeks of age. They were given standard chow and water ad libitum except for the pair-feeding experiment.
The animals were housed in individual cages in a temperature-, humidity-and light-controlled room (lights on at 08.00 h and off at 20.00 h). All animal experiments were conducted according to the guidelines of Sumitomo Pharmaceuticals Committee on Animal Research.
Recombinant BDNF and leptin
Human recombinant BDNF (Regeneron Pharmaceuticals, Tarrytown, NY, USA) and mouse recombinant leptin (PeproTech, Rocky Hill, NJ, USA) were used in this study. Phosphate-buffered saline (PBS) or 0.01% Tween-80 and 1% mannitol in PBS were used as vehicles.
Study protocols
(1) Acute studies. DIO and KKA y mice were injected intraperitoneally (i.p.) with BDNF (10 mg/kg), leptin (10 mg/kg) or vehicle at 8.00 h and 20.00 h. Cumulative food intake over 24 h was determined by recording the amount of chow remaining in the food dishes. We preliminarily observed that 5, 10 and 20 mg/kg of BDNF dose-dependently reduced food intake and improved glucose tolerance in DIO mice (data not shown). Furthermore, we also treated normal mice with 1, 2, 5 and 10 mg/kg of leptin and found that 10 mg/kg of leptin causes a significant reduction in food intake (data not shown). Therefore, we injected DIO and KKA y mice with BDNF and leptin at a dose of 10 mg/kg. (2) Repetitive administration studies. DIO mice were injected subcutaneously (s.c.) with BDNF (10 mg/kg), leptin (10 mg/ kg) or vehicle once daily for 6 days. Food intake was determined every 24 h by recording the amount of chow remaining in the food dishes. Average food intake (g/mouse/ day) of each treatment group during experimental period is indicated in Figure 2a . Vehicle-treated groups were fed either ad libitum or the amount of chow consumed by the BDNFtreated groups during the preceding 24 h (pair-feeding experiment). Before the last injection, blood was sampled for the measurement of serum leptin and plasma insulin concentrations. Oral glucose tolerance test (OGTT) was performed 24 h after the last injection. The KKA y mice were injected s.c. with BDNF (20 mg/kg) once daily for 28 days. Body weight, food intake and blood glucose concentrations were measured on the indicated days ( Figure 4 ).
BDNF and leptin resistance T. Nakagawa et al (3) ICV injection experiments. For ICV injection, db/db mice were anesthetized with diethyl ether. The bregma was identified and 15 mg BDNF, with or without 0.05 mg of SHU9119 (Phoenix Pharmaceuticals, Mountain View, CA, USA), was injected into the lateral ventricle. We determined the dose of SHU9119 injected (0.05 mg) from determining the amount that was enough to inhibit the leptin-induced reduction of food intake. 29 Artificial cerebrospinal fluid 29 was used as vehicle for ICV injection. Cumulative food intake, body weight change and blood glucose concentration were measured 48 h after ICV injection.
Blood glucose, leptin and insulin measurements Blood was sampled from the tail vein, and blood glucose was measured by the GLUCOSE C II-TEST WAKO (Mutarotaseglucose oxidase method, Wako Chemical, Osaka, Japan). Serum leptin and plasma insulin concentrations were measured by the respective ELISAs (AN'ALYZA mouse leptin, Genzyme TECHNE, Minneapolis, MN, USA and Levisinsulin-mouse, Shibayagi, Gunma, Japan).
Oral glucose tolerance test (OGTT)
After overnight fasting, 3 g/kg D-glucose was administered orally to DIO mice. Blood glucose concentrations were measured at 0 (before), 15, 45, 90 and 135 min after glucose administration. Plasma insulin concentrations were also measured at 0 (before) and 15 min after glucose administration.
Statistical analysis
All data are presented as means7s.d. Differences between individual groups were analyzed by Student's t-test. Statistical calculations were performed using SAS software (SAS Institute, Cary, NC, USA). Po0.05 was considered statistically significant.
Results
Acute effect of BDNF in DIO mice i.p. injection of recombinant leptin (10 mg/kg, twice daily) caused a marked reduction of cumulative food intake in mice fed a standard diet for 24 h (68% of those in vehicle-treated groups; n ¼ 8, Po0.01) (Figure 1a ). In contrast, treatment with 10 mg/kg leptin did not affect food intake of DIO mice (n ¼ 8) (Figure 1b) , which is consistent with previous reports. 23, 25 In this study, 10 mg/kg BDNF treatment caused a slight reduction of cumulative food intake in standard dietfed mice (83 and 90% of that of vehicle-treated groups over 12 and 24 h, respectively; n ¼ 8, Po0.05 at 12 h) ( Figure 1a ). In contrast, treatment with BDNF at a dose that did not affect food intake in standard diet-fed mice reduced food intake of DIO mice over 24 h (36% of that of vehicle-treated groups; n ¼ 8, Po0.01) (Figure 1b ).
Repetitive administration of BDNF in DIO mice
We next examined the effect of repetitive administration with BDNF (10 mg/kg/day for 6 days) in DIO mice. In standard diet-fed mice, repetitive administration of BDNF for 6 days did not affect food intake (Figure 2a) , and reduced body weight slightly but significantly (96% of that of vehicle-treated groups; n ¼ 8, Po0.05) (Figure 2b ). During daily administration, food intake of BDNF-treated DIO mice was significantly lower than vehicle-treated groups (1.370.3 vs 2.570.4 g/mouse/day, n ¼ 8, Po0.01) (Figure 2a ). Body weight of BDNF-treated DIO mice was significantly lower than that of vehicle-treated DIO mice 3 and 6 days after the start of administration (40.171.9 vs 44.571.6 g at day 6, n ¼ 8, Po0.01) (Figure 2b ). There was no significant difference in body weight between BDNF-treated and pair-fed DIO mice (Figure 2b ), indicating that the antiobesity effect of BDNF is due to decreased food intake in DIO mice. As reported previously, 23, 24 serum leptin concentrations in high-fat diet-fed groups were significantly higher than those in standard diet-fed groups (74.8725.4 vs 10.578.1 ng/ml, n ¼ 8, Po0.01) (Figure 2c ). Repetitive administration of BDNF for 6 days significantly lowered serum leptin concen- BDNF and leptin resistance T. Nakagawa et al trations in DIO mice compared with vehicle-treated groups (36.478.7 vs 74.8725.4 ng/ml, n ¼ 8, Po0.01) (Figure 2c ). Pair feeding of vehicle-treated DIO mice with the same amount of chow consumed by the BDNF-treated groups lowered serum leptin concentrations to comparable levels, indicating that serum leptin concentrations are reduced in parallel with decreased food intake, and possibly body weight reduction. As expected, BDNF did not lower serum leptin concentrations in standard diet-fed mice (Figure 2c ).
Effect of BDNF on glucose metabolism in DIO mice
The nonfasting plasma insulin concentrations in DIO mice were significantly higher than those in mice fed a standard diet (4.371.8 vs 1.270.5 ng/ml, n ¼ 8, Po0.01) (Figure 2d ). Repetitive administration of BDNF significantly lowered plasma insulin concentrations in DIO mice relative to those in vehicle-treated groups (2.671.0 vs 4.371.8 ng/ml, n ¼ 8, Po0.05), which was roughly comparable to those in pair-fed groups (1.270.6 ng/ml, n ¼ 8) (Figure 2d ). In this study, there was no significant difference in plasma insulin concentrations between vehicle-and BDNF-treated standard diet-fed mice (Figure 2d ). We also performed OGTT after repetitive administration of BDNF. After overnight fasting, blood glucose concentrations in BDNF-treated DIO mice were significantly lower than those in vehicle-treated DIO mice (91.479.5 vs 131.0713.6 mg/dl, n ¼ 8, Po0.01) (Figure 3a) . The area under the curve (AUC) of blood glucose of BDNFtreated DIO mice was significantly lower than vehicletreated DIO mice during OGTT (23 40071100 vs 31 80075800 mg/dl min, n ¼ 8, Po0.01) (Figure 3b ). Furthermore, BDNF significantly reduced plasma insulin concentration compared to vehicle-treated groups (0.670.2 vs. 1.370.7 ng/ml, n ¼ 8, Po0.01) (Figure 3c ). Pair feeding of vehicle-treated DIO mice with the same amount of chow consumed by the BDNF-treated groups did not show improvement in glucose metabolism (fasting blood glucose and insulin concentrations, and impaired glucose tolerance as revealed by OGTT) (Figure 3a-c) , suggesting that BDNF can ameliorate impaired glucose tolerance in DIO mice independent of its hypophagic effect. (Figure 4a ), indicating a state of leptin resistance, as has been reported. 28 However, treatment with BDNF markedly reduced cumulative food intake relative to vehicle-treated groups (5.670.7 vs 7.270.9 g/mouse/24 h, n ¼ 8, Po0.01) (Figure 4a ). We also examined the effect of repetitive administration of BDNF (20 (Figure 5a ). Co-injection with SHU9119 did not affect the BDNF-induced inhibition of food intake ( Figure 5a ). BDNF-induced body weight change was also not affected by co-injection with SHU9119 (À2.670.4 vs À3.670.7 g, n ¼ 6-7) (Figure 5b ). Blood glucose concentrations in BDNF-treated db/db mice were significantly reduced compared to vehicle-treated groups (162.5741.8 vs 323.3730.1 mg/dl, n ¼ 6-7, Po0.01) (Figure 5c ). ICV coinjection with SHU9119 did not affect BDNF-induced reduction of blood glucose concentration (Figure 5c ). In this study, ICV injection of SHU9119 alone did not affect food intake, body weight or blood glucose concentration in db/db mice.
Discussion
Obesity is a heterogeneous group of disorders that arise from complex interactions between genetic and environmental factors, however the underlying mechanism is poorly understood. Whatever the mechanism may be, obesity is usually associated with hyperleptinemia, except for a rare monogenic form of obesity with leptin gene mutations, 5, 7, 9 suggesting that leptin resistance may represent a common basis for obesity. We and other groups have demonstrated that BDNF can ameliorate hyperphagia and hyperglycemia of leptin receptor-deficient db/db mice [13] [14] [15] [16] [17] and speculated that BDNF might be effective in leptin-resistant obesity and diabetes. This study was designed to elucidate whether or not BDNF is capable of exerting its antiobesity and antidiabetic effects in two different rodent models of leptin resistance: an This study demonstrated that peripheral administration of BDNF can acutely reduce food intake and body weight of DIO and KKA y mice, both of which are unresponsive to leptin. We have also found that repetitive administration of BDNF can ameliorate hyperphagia or obesity and impaired glucose metabolism or diabetes in these animals. Although the BDNF administration of the longer period is required, these observations suggest the therapeutic potential of BDNF in the treatment of obesity and diabetes of various causes. In this study, pair feeding of vehicle-treated DIO mice with the same amount of food as consumed by the BDNF-treated groups reduced body weight but did not affect glucose homeostasis. These observations indicate that the antiobesity effect of BDNF is solely due to decreased food intake, whereas its antidiabetic effect is not evident in DIO mice. The mechanism by which BDNF can be effective in leptinresistant obesity and diabetes is not clear at present. Recently, El-Haschimi et al. have provided evidence that at least two defects underlie leptin resistance that develops during the course of DIO: a defect in leptin access to the hypothalamus and an intracellular signaling defect in hypothalamic neurons. 30 Evidence has accumulated indicating that BDNF can also exert its antiobesity and antidiabetic effects via a hypothalamic mechanism. 16, 17 Since peripheral administration of BDNF is effective in improving obesity and hyperglycemia in DIO mice, the brain transport of BDNF is likely regulated differently from that of leptin. Upon binding to its cognate receptor, leptin activates Janus proteintyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) and mitogen-activated protein kinase (MAPK) pathways [31] [32] [33] . In contrast, BDNF binds to its tyrosine kinase-coupled receptor, TrkB, which, upon ligand binding, forms homodimers and induces autophosphorylation on tyrosine residues, thereby initiating the activation of MAPK and phosphoinositol-3-kinase pathways. [34] [35] [36] We speculate that BDNF is effective in leptin-resistant obesity and diabetes because BDNF differs from leptin in its intracellular signaling capabilities as well as regulation of the brain transport system. We and other groups have demonstrated that the antiobesity effect of leptin is mediated by the hypothalamic melanocortin system. 29, 37 Thus, KKA y mice develop leptinresistant obesity and diabetes at least partly because of antagonism of the hypothalamic melanocortin system by ectopic expression of the agouti protein. 27 Given that BDNF is effective in improving obesity and diabetes in KKA y mice, it is likely that the antiobesity and antidiabetic effects of BDNF do not require the activity of the hypothalamic 
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T. Nakagawa et al melanocortin system. This study demonstrates that ICV coinjection with SHU9119 does not affect the antiobesity and antidiabetic actions of BDNF in db/db mice. It is, therefore, likely that MC4-R signaling does not play a major role in the antiobesity and antidiabetic effects of BDNF. This notion is consistent with our observation that BDNF does not affect hypothalamic expression of mRNAs for proopiomelanocortin and agouti-related protein, an endogenous agonist and antagonist of the hypothalamic melanocortin system, in DIO mice (Nakagawa T et al, unpublished data). These observations, taken together, support the notion that BDNF may regulate food intake and glucose homeostasis differently from leptin. It has been demonstrated that ciliary neurotrophic factor (CNTF), a member of the neurotrophin family, reduces food intake and body weight in leptin-resistant DIO mice. 38, 39 Therefore, BDNF is a second neurotrophin that is effective in leptin-resistant obesity and diabetes. It seems, however, that BDNF and CNTF act differently in the regulation of energy homeostasis. For instance, CNTF can reduce potently food intake and body weight in mice fed either standard or highfat diets. [38] [39] [40] In contrast, this study demonstrates that BDNF can reduce food intake and body weight in mice fed a highfat diet, whereas it does so only slightly in mice fed a standard diet. It has also been reported that the antiobesity effect of CNTF is long-lasting in DIO mice and does not induce rebound, even after treatment cessation. 39 However, we observed that in KKA y mice food intake and blood glucose concentrations return to pretreatment levels a week after the cessation of BDNF treatment (Nakagawa T et al, unpublished data). CNTF exerts its biological actions through a multisubunit receptor complex composed of a ligand-specific subunit (CNTFR-a) and two signal-transducing subunits, gp130 and leukemia inhibitory factor receptor (LIFR). 41, 42 Both gp130 and LIFR share relatively high sequence homology and thus signaling capabilities with the leptin receptor. 31, 43 CNTF can also stimulate JAK/STAT and MAPK pathways. 41, 42 The different signal transduction pathways activated by BDNF and CNTF may explain the different effects of BDNF and CNTF on energy homeostasis. The above discussion also suggests that BDNF in combination with CNTF can be a useful tool in investigating the molecular basis for leptin resistance.
In conclusion, we have demonstrated that BDNF can exert its antiobesity and antidiabetic effects in two different rodent models of leptin resistance, DIO and KKA y mice.
We, therefore, postulate the therapeutic potential of BDNF in the treatment of leptin-resistant obesity and diabetes. This study has also highlighted the differential mechanisms regulating antiobesity and antidiabetic effects of BDNF and leptin, thereby demonstrating that BDNF is a useful tool in investigating the molecular mechanism of leptin resistance. BDNF and leptin resistance T. Nakagawa et al
